A single MHCII neoepitope mRNA vaccine elicits CD4 T- and B- cell responses promoting endogenous CD8 anti-tumor immunity
Capietto, A.-H.; Balanca, C.-C.; Bouziat, R.; Wu, T.; Gober, J.; Carbone, C.; Nissenbaum, A.; Hoshyar, R.; Yadav, M.; Gutierrez, A.; Chestnut, Y.; Javinal, V.; Menon, H.; Darmanis, S.; de Simone, M.; Sun, Y.; Seshasayee, D.; Paluch, M.; Bulutoglu, B.; Jones, T.; Wang, Y.; Liao, L.; Duong, E.; Anand, A.; Antonelli, A.; Oei, Y.; Cheung, J.; Luoh, S.-M.; Ziai, J.; Preston, J.; Hung, J.; Freund, E.; Wichner, S.; Oh, J.; Tahtinen, S.; Sahin, U.; ElSohly, A.; Schartner, J.; Delamarre, L.; Mellman, I.; Linehan, J.
Show abstract
Recent progress in therapeutic cancer vaccines has shown promising clinical activity, especially when targeting MHC class I (MHCI) neoantigen-specific CD8+ T cell responses in post-surgical patients. To explore the role of CD4+ T cells in vaccine-dependent tumor rejection, we constructed an mRNA lipoplex vaccine encoding a single MHCII-restricted neoantigen. The vaccine elicited Tfh and Th1 cell responses while decreasing Tregs, leading to rejection of established tumors in mice. IL-21 and IFN-{gamma}, crucial for Tfh and Th1 function respectively, contributed to anti-tumor activity. B cells and neoantigen-specific antibodies were also shown to participate in vaccine efficacy. Additionally, conventional type 1 dendritic cells (cDC1s) were essential for eliciting vaccine-induced CD4+ T cells, and both cDC1s and CD4+ T cells were required to enhance endogenous CD8+ responses, which were crucial for tumor control. Our results suggest that immunizing against MHCII neoantigens alone is sufficient to orchestrate a potent and cooperative immune response against cancer.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Intratumor Childhood Vaccine-Specific CD4+ T cell Recall Coordinates Antitumor CD8+ T cells and Eosinophils 98%
- Tumor-Specific CD8+ T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating Lymphocytes 97%
- Distinct sets of molecular characteristics define tumor-rejecting neoantigens 97%
Similar papers in this journal
- A single cell atlas reveals distinct immune landscapes in transplant and primary tumors that determine response or resistance to immunotherapy 97%
- TGF--dependent Lymphoid Tissue Residency of Stem-like T cells Limits the Response to Tumor Vaccine 97%
- T cell receptor and IL-2 signaling strength control memory CD8+ T cell functional fitness via chromatin remodeling 96%
Similar papers in this journal
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses 97%
- A reservoir of stem-like CD8 T cells in the tumor-draining lymph node maintains the ongoing anti-tumor immune response 97%
- Distinct CD8+ T Cell Programming in the Tumor Microenvironment Contributes to Sex Bias in Bladder Cancer Outcome 96%
Similar papers in this journal
- Clonal spreading of tumor-infiltrating T cells underlies the robust antitumor immune responses 97%
- Microenvironmental correlates of immune checkpoint inhibitor response in human melanoma brain metastases revealed by T cell receptor and single-cell RNA sequencing 96%
- Single-cell clonal lineage tracing identifies the transcriptional program controlling the cell fate decisions by neoantigen-specific CD8+ T cells 96%
Similar papers in this journal
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 98%
- Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment 97%
- Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.